FDA Approves New Dosing Options for Hizentra® The U.S. Food and Drug Administration (FDA) has approved the administration options for CSL Behring's Hizentra® (Immune Globulin Subcutaneous (Human), 20% Liquid) to include the ability to individualize therapy with flexible dosing—treatment at regular intervals from daily to once every two weeks (biweekly)—for people with primary...